ADPT
Adaptive Biotechnologies Corp
NASDAQ · Healthcare · Biotechnology · US
$28.61
+0.21%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$28.55
From 52W high−68.03%
Volume2.99M
Market cap$4.57B
P/E (TTM)—
P/S (TTM)14.8x
Div yield—
Key dataSep 18, 2026
Open
$28.55
From 52W high
−68.03%
Volume
2.99M
Market cap
$4.57B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−290.7x
P/E (TTM)
—
RSI (14)
56.8
MomentumView details →
1D Return
+0.21%
YTD Return
−56.26%
SummaryUpdated Jun 1, 2026
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a commercial-stage biotechnology company founded in 2009 and headquartered in Seattle, Washington. The company was originally incorporated as Adaptive TCR Corporation before changing its name in December 2011. Adaptive went public in June 2019 and has since established itself as a leader in immune medicine platform development. The company focuses on leveraging the adaptive immune system to develop diagnostic tests and therapeutic treatments for various diseases including cancer, autoimmune conditions, and infectious diseases.
Similar companies
Latest newsMore news →
The National Comprehensive Cancer Network updated its Clinical Practice Guidelines in Oncology for Multiple Myeloma to strengthen routine MRD assessment recommendations and specifically reference Adaptive Biotechnologies' clonoSEQ assay.3d agoHarlan Robins, co-founder of Adaptive Biotechnologies, raised $15 million for a new startup focused on rethinking how AI trains on scientific data.33d agoAdaptive Biotechnologies reported financial results for the second quarter of 2026.53d ago